Research and Markets - China rhEPO Market CAGR Growth of 16.89% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: 3S Bio, Sihuan, LG Life Sciences

DUBLIN, July 12, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "rhEPO Market in China 2016-2020" report to their offering.

The report forecasts the recombinant human erythropoietin (rhEPO) market in China to grow at a CAGR of 16.89% during the period 2016-2020.

Commenting on the report, an analyst from the research team said: A major trend which will boost market growth is the exploitation of novel therapeutic methods. The use of EPO has expanded to therapeutic areas other than for the treatment of anemia. For instance, recombinant EPO therapy is used to treat cardio-renal anemia syndrome. Use of EPO has shown an improvement in left and right ventricular systolic function in such patients with the reduction in cardiac remodeling, brain natriuretic peptide (BNP) levels, and hospitalization rate. Apart from this, with the discovery of EPO receptors in non-erythroid tissues, EPO has been investigated as a novel therapeutic agent in diseases and therapeutic conditions, including spinal cord injury, depression, diabetes, and as an immunomodulating agent.

According to the report, a key growth driver is the increase in CKD and dialysis patient population. An increase in the anemic population is expected to boost the market growth as EPO drugs are used as a treatment option for anemia. Anemia can be caused due to a number of diseases such as kidney disease, cancer, and HIV. In individuals with CKD, anemia develops due to the dysfunction of the kidneys. In this condition, the levels of EPO are low, which results in the development of anemia. Also, deficiency of iron, vitamin B12, and folic acid, which are essential for forming hemoglobin by RBCs, can result in anemia. The condition is aggravated in individuals undergoing dialysis; 80% of the individuals on dialysis are on EPO therapy to treat anemia

Questions Answered:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Companies Mentioned:

• 3S Bio
• Shanghai Chemo
• Chengdu Di'ao
• NCPC Genetech
• Kyowa Hakko Kirin
• Shandong Kexing
• Ahua Pharmaceutical
• Biosidus
• Dragon Pharma
• Huaxin High Biotechnology
• Kehua Bio-Engineering
• LG Life Sciences
• Shenzhen Sai Bao Er Bio-Pharmaceutical
• Sihuan
• Shenyang Sunshine Pharmaceutical
• Uni-Bio Science Group
• Wanbang Biochemical Pharmaceuticals
  

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Erythropoietin: An overview

PART 06: Global erythropoietin market

PART 07: China: Country snapshot

PART 08: Opportunities for pharmaceutical vendors in China

PART 09: Biopharmaceutical market in China

PART 10: Market landscape

PART 11: Market segmentation by end-user

PART 12: Market segmentation by application

PART 13: Drug pricing and reimbursement in China

PART 14: Pipeline portfolio

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape

PART 21: Appendix

PART 22: About the Author

For more information visit http://www.researchandmarkets.com/research/wj2wfz/rhepo_market_in

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com